Literature DB >> 11509894

Why do alexithymic features appear to be stable? A 12-month follow-up study of a general population.

K Honkalampi1, H Koivumaa-Honkanen, A Tanskanen, J Hintikka, J Lehtonen, H Viinamäki.   

Abstract

BACKGROUND: This 12-month follow-up study investigated the prevalence of alexithymia and its relationship with depression in a sample of the general population from Eastern Finland (n = 1,584).
METHODS: Alexithymia was assessed using the 20-item version of the Toronto Alexithymia Scale (TAS) and depression using the 21-item Beck Depression Inventory (BDI).
RESULTS: The prevalence of alexithymia in each study phase was similar (baseline: 9.7%; follow-up: 10.1%). Mean values of BDI, TAS-20 and subfactors of the TAS-20 also remained unchanged between the study phases. However, by using the original cutoff points, we found that a proportion of the subjects were in a different TAS-20 category on follow-up than at baseline. The mean values of BDI had not changed in those subjects who had similar alexithymia status in both phases, but increased or decreased in parallel with the change in TAS-20 score among all other subjects.
CONCLUSIONS: Our findings indicate that it is important to use a variety of viewpoints when studying changes in alexithymia status. Alexithymia appears to be a stable trait based on the similarity of the mean TAS-20 scores in separate study phases. However, when focusing on the changes in alexithymia status at the individual level, alexithymic features also appear to be state dependent and strongly related to depressive symptoms. Copyright 2001 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2001        PMID: 11509894     DOI: 10.1159/000056262

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  14 in total

Review 1.  Development of alexithymic personality features.

Authors:  Max Karukivi; Simo Saarijärvi
Journal:  World J Psychiatry       Date:  2014-12-22

2.  The predictive value of the Toronto Alexithymia Scale among patients with asthma.

Authors:  Jonathan M Feldman; Paul M Lehrer; Stuart M Hochron
Journal:  J Psychosom Res       Date:  2002-12       Impact factor: 3.006

3.  Alexithymia and anxiety sensitivity in patients with non-cardiac chest pain.

Authors:  Kamila S White; Cassandra J McDonnell; Ernest V Gervino
Journal:  J Behav Ther Exp Psychiatry       Date:  2011-04-19

4.  Obesity, alexithymia and psychopathology: a case-control study.

Authors:  F Pinna; L Lai; S Pirarba; W Orrù; F Velluzzi; A Loviselli; B Carpiniello
Journal:  Eat Weight Disord       Date:  2011-02-16       Impact factor: 4.652

5.  Age and gender effect on alexithymia in large, Japanese community and clinical samples: a cross-validation study of the Toronto Alexithymia Scale (TAS-20).

Authors:  Yoshiya Moriguchi; Motonari Maeda; Tetsuya Igarashi; Toshio Ishikawa; Masayasu Shoji; Chiharu Kubo; Gen Komaki
Journal:  Biopsychosoc Med       Date:  2007-03-06

6.  Effects of Self-Rated Health and Self-Rated Economic Situation on Depressed Mood Via Life Satisfaction Among Older Adults in Costa Rica.

Authors:  Benjamín Reyes Fernández; Luis Rosero-Bixby; Heli Koivumaa-Honkanen
Journal:  J Aging Health       Date:  2015-06-19

7.  Selective impairment of decision making under ambiguity in alexithymia.

Authors:  Lei Zhang; Xue Wang; Yu Zhu; Hongchen Li; Chunyan Zhu; Fengqiong Yu; Kai Wang
Journal:  BMC Psychiatry       Date:  2017-11-28       Impact factor: 3.630

8.  The Multifaceted Nature of Alexithymia - A Neuroscientific Perspective.

Authors:  Katharina S Goerlich
Journal:  Front Psychol       Date:  2018-08-29

9.  The Relationship between Alexithymia and General Symptoms of Patients with Depressive Disorders.

Authors:  Ju Hee Kim; Seung Jae Lee; Hyo Deog Rim; Hea Won Kim; Geum Ye Bae; Sung Man Chang
Journal:  Psychiatry Investig       Date:  2008-09-30       Impact factor: 2.505

10.  Parallel but independent reduction of emotional awareness and corpus callosum connectivity in older age.

Authors:  Martine Skumlien; Donatas Sederevicius; Anders M Fjell; Kristine B Walhovd; René Westerhausen
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.